NCT05196581View on ClinicalTrials.gov

Efficacy of Breathox Device Inhalation Therapy in the Treatment of Acute Symptoms Associated With COVID-19 and in the Prevention of the Use of Health Resources

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

December 1, 2021

Primary Completion Date

July 1, 2022

Study Completion Date

December 31, 2022

Conditions
COVID-19
Interventions
DRUG

Dispersible NaCl powder 10 sessions

Dispersible NaCl powder 10 sessions

DRUG

Dispersible NaCl powder 5 sessions

Dispersible NaCl powder 5 sessions

Trial Locations (1)

18618687

Hospital das Clínicas da Faculdade de Medicina de Botucatu, Botucatu

All Listed Sponsors
collaborator

Liita Care ApS

INDUSTRY

lead

Suzana Erico Tanni Minamoto

OTHER

NCT05196581 - Efficacy of Breathox Device Inhalation Therapy in the Treatment of Acute Symptoms Associated With COVID-19 and in the Prevention of the Use of Health Resources | Biotech Hunter | Biotech Hunter